NLS Pharmaceutics (NLS Pharmaceutics) Current Accrued Expense : $1.65 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Current Accrued Expense?

NLS Pharmaceutics's Current Accrued Expense for the quarter that ended in Dec. 2023 was $1.65 Mil.

NLS Pharmaceutics's quarterly Current Accrued Expense declined from Dec. 2022 ($0.98 Mil) to Jun. 2023 ($0.76 Mil) but then increased from Jun. 2023 ($0.76 Mil) to Dec. 2023 ($1.65 Mil).

NLS Pharmaceutics's annual Current Accrued Expense increased from Dec. 2021 ($0.66 Mil) to Dec. 2022 ($0.98 Mil) and increased from Dec. 2022 ($0.98 Mil) to Dec. 2023 ($1.65 Mil).

NLS Pharmaceutics Current Accrued Expense Historical Data

The historical data trend for NLS Pharmaceutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics Current Accrued Expense Chart

NLS Pharmaceutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

0.84

1.37

0.66

0.98

1.65

NLS Pharmaceutics Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial								0.66	0.51	0.98	0.76	1.65

NLS Pharmaceutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

NLS Pharmaceutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

The Circle 6, Zurich, CHE, 8058

Website

https://www.nlspharma.com

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.